957881-03-7

Basic information

• Product Name: AZD1152
• Synonyms: 3-[[7-[3-[Ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-5-acetamide;AZD1152 (Barasertib);2-(ETHYL(3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE
• CAS NO: 957881-03-7
• Molecular Formula: C₂₆H₃₁FN₇O₆P
• Molecular Weight: 586.5318642
• EINECS: -0
• Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 957881-03-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.463
• CAS DataBase Reference: AZD1152(CAS DataBase Reference)
• NIST Chemistry Reference: AZD1152(957881-03-7)
• EPA Substance Registry System: AZD1152(957881-03-7)

Safety Data

• Hazardous Substances Data: 957881-03-7(Hazardous Substances Data)

Usage

Description

AZD1152 is a pharmaceutical compound that functions as an Aurora kinase inhibitor. It is designed to target and inhibit the activity of Aurora kinases, which are key enzymes involved in cell division and have been implicated in the development and progression of various cancers. By inhibiting these enzymes, AZD1152 aims to disrupt the cell cycle and prevent the growth and spread of cancer cells.

Uses

Used in Oncology:
AZD1152 is used as an anticancer agent for the treatment of patients with advanced solid tumors. Its mechanism of action involves the inhibition of Aurora kinases, which play a crucial role in the regulation of the cell cycle and are often overexpressed or mutated in cancer cells. This inhibition can lead to the prevention of tumor growth and the reduction of cancer cell proliferation.

Upstream product

• 372-19-0 meta-fluoroaniline 
• 446-32-2 4-fluoroanthranilic acid 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 557770-91-9 2-(3-((7-(3-chloropropoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)acetic acid 
• 557770-90-8 4-chloro-7-(3-chloropropoxy)quinazoline 
• 557770-89-5 4-(3-phenylpropylamino)-7-(2-chloroethoxy)quinazoline 
• 722544-50-5 di-tert-butyl 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl phosphate 
• 722544-51-6 N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide 
• 174891-10-2 (5-amino-2H-pyrazol-3-yl)acetic acid 
• 722544-46-9 2-(5-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-2H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide 

Relevant articles and documents

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

The Aurora kinases have been the subject of considerable interest as targets for the development of new anticancer agents. While evidence suggests inhibition of Aurora B kinase gives rise to the more pronounced antiproliferative phenotype, the most clinically advanced agents reported to date typically inhibit both Aurora A and B. We have discovered a series of pyrazoloquinazolines, some of which show greater than 1000-fold selectivity for Aurora B over Aurora A kinase activity, in recombinant enzyme assays. These compounds have been designed for parenteral administration and achieve high levels of solubility by virtue of their ability to be delivered as readily activated phosphate derivatives. The prodrugs are comprehensively converted to the des-phosphate form in vivo, and the active species have advantageous pharmacokinetic properties and safety pharmacology profiles. The compounds display striking in vivo activity, and compound 5 (AZD1152) has been selected for clinical evaluation and is currently in phase 1 clinical trials.

PROCESS AND INTERMEDIATE

The invention relates to a new process useful in the preparation of pharmaceutical compounds such as 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate (AZD1152) and intermediates used therein.